PROCEPT BioRobotics Corp PRCT
PRCT among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
PRCT and 9 peers, year by year
The 9 Health care companies closest to PRCT in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics Corp | FY2025 | $308.1M | +37.2% | 63.7% | −33.7% | −31.0% | −18.9% | −26.1% | 0.14 |
| VCEL Vericel Corp | FY2025 | $276.3M | +16.5% | 74.4% | 4.0% | 6.0% | 9.0% | 4.7% | - |
| RYTM Rhythm Pharmaceuticals, Inc. | FY2025 | $189.8M | +45.8% | - | −101.2% | −103.6% | −61.5% | −141.3% | 0.78 |
| TWST Twist Bioscience Corp | FY2025 | $376.6M | +20.3% | - | −36.2% | −20.6% | −20.1% | −16.4% | - |
| LMAT Lemaitre Vascular Inc | FY2025 | $249.6M | +13.5% | 71.5% | 27.2% | 23.1% | 29.8% | 14.7% | - |
| ZLAB Zai Lab Ltd | FY2025 | $460.2M | +15.0% | - | −49.9% | −38.1% | −34.5% | −24.5% | 0.29 |
| LGND Ligand Pharmaceuticals Inc | FY2025 | $268.1M | +60.4% | - | 15.3% | 46.4% | 18.2% | 12.2% | - |
| WGS GeneDx Holdings Corp. | FY2025 | $427.5M | +40.0% | 69.7% | −3.1% | −4.9% | 3.3% | −6.8% | 0.18 |
| KRYS Krystal Biotech, Inc. | FY2025 | $389.1M | +33.9% | - | 41.5% | 52.6% | 48.5% | 16.8% | - |
| RVMD Revolution Medicines, Inc. | FY2025 | $0 | - | - | - | - | - | −69.3% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2020 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2020 to FY2025
Revenue as reported in the 10-K.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | $7.7M | $34.5M | $75.0M | $136.2M | $224.5M | $308.1M |
| VCEL Dec | $124.2M | $156.2M | $164.4M | $197.5M | $237.2M | $276.3M |
| RYTM Dec | $0 | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| TWST Sep | $90.1M | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| LMAT Dec | $129.4M | $154.4M | $161.7M | $193.5M | $219.9M | $249.6M |
| ZLAB Dec | $49.0M | $144.3M | $215.0M | $266.7M | $399.0M | $460.2M |
| LGND Dec | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| WGS Dec | $179.3M | $212.2M | $234.7M | $202.6M | $305.4M | $427.5M |
| KRYS Dec | - | $0 | $0 | $50.7M | $290.5M | $389.1M |
| RVMD Dec | $43.0M | $29.4M | $35.4M | $11.6M | $0 | $0 |
| Peer median | $107.1M | $144.3M | $164.4M | $193.5M | $237.2M | $276.3M |
Sales growth, FY2020 to FY2025
Revenue against the fiscal year before.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | - | +347% | +118% | +81.6% | +64.8% | +37.2% |
| VCEL Dec | +3.5% | +25.5% | +6.9% | +20.7% | +20.1% | +16.5% |
| RYTM Dec | - | - | +649% | +228% | +68.1% | +45.8% |
| TWST Sep | +65.7% | +46.9% | +53.8% | +20.4% | +27.7% | +20.3% |
| LMAT Dec | +10.4% | +19.4% | +4.7% | +19.7% | +13.6% | +13.5% |
| ZLAB Dec | +277% | +194% | +47.6% | +25.4% | +49.1% | +15.0% |
| LGND Dec | +55.0% | +47.7% | −18.8% | −33.1% | +27.3% | +60.4% |
| WGS Dec | −8.6% | +18.3% | +10.6% | −13.7% | +50.8% | +40.0% |
| KRYS Dec | - | - | - | - | +473% | +33.9% |
| RVMD Dec | −14.1% | −31.6% | +20.4% | −67.3% | −100% | - |
| Peer median | +10.4% | +25.5% | +15.5% | +20.1% | +27.7% | +27.1% |
Gross margin, FY2020 to FY2025
Gross profit / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| VCEL Dec | 67.8% | 67.9% | 66.8% | 68.6% | 72.6% | 74.4% |
| RYTM Dec | - | - | - | - | - | - |
| TWST Sep | - | - | - | - | - | - |
| LMAT Dec | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| ZLAB Dec | - | - | - | - | - | - |
| LGND Dec | - | - | - | - | - | - |
| WGS Dec | 2.2% | −7.8% | −11.4% | 44.4% | 63.6% | 69.7% |
| KRYS Dec | - | - | - | - | - | - |
| RVMD Dec | - | - | - | - | - | - |
| Peer median | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
Operating margin, FY2020 to FY2025
Operating income / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −619.4% | −157.1% | −107.6% | −80.2% | −43.0% | −33.7% |
| VCEL Dec | 1.9% | −5.0% | −10.4% | −3.3% | 1.9% | 4.0% |
| RYTM Dec | - | n/m | −757.9% | −238.1% | −204.0% | −101.2% |
| TWST Sep | −155.5% | −115.4% | −115.3% | −88.6% | −70.6% | −36.2% |
| LMAT Dec | 22.3% | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| ZLAB Dec | −616.4% | −485.1% | −188.0% | −137.4% | −70.7% | −49.9% |
| LGND Dec | 22.9% | 43.0% | 1.5% | 9.1% | −13.5% | 15.3% |
| WGS Dec | −134.9% | −210.3% | −284.5% | −89.2% | −7.6% | −3.1% |
| KRYS Dec | - | - | - | −216.2% | 22.6% | 41.5% |
| RVMD Dec | −257.5% | −639.7% | −730.0% | n/m | - | - |
| Peer median | −134.9% | −115.4% | −151.7% | −88.9% | −10.6% | 0.5% |
Net margin, FY2020 to FY2025
Net income / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −687.0% | −173.6% | −116.2% | −77.8% | −40.7% | −31.0% |
| VCEL Dec | 2.3% | −4.8% | −10.2% | −1.6% | 4.4% | 6.0% |
| RYTM Dec | - | n/m | −766.2% | −238.5% | −200.3% | −103.6% |
| TWST Sep | −155.3% | −114.9% | −107.0% | −83.5% | −66.7% | −20.6% |
| LMAT Dec | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| ZLAB Dec | −549.3% | −488.2% | −206.1% | −125.5% | −64.4% | −38.1% |
| LGND Dec | −1.8% | 23.7% | −17.0% | 39.7% | −2.4% | 46.4% |
| WGS Dec | −134.6% | −115.6% | −233.9% | −86.8% | −17.1% | −4.9% |
| KRYS Dec | - | - | - | 21.6% | 30.7% | 52.6% |
| RVMD Dec | −251.6% | −636.6% | −703.0% | n/m | - | - |
| Peer median | −134.6% | −114.9% | −156.6% | −42.5% | −9.8% | 0.5% |
Free cash flow, FY2020 to FY2025
Cash from operations minus capital spending.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −$48.6M | −$57.9M | −$83.0M | −$133.2M | −$103.6M | −$58.3M |
| VCEL Dec | $14.9M | $21.1M | $10.1M | $15.3M | −$5.8M | $24.7M |
| RYTM Dec | −$122.2M | −$146.4M | −$173.7M | −$136.2M | −$113.9M | −$116.6M |
| TWST Sep | −$152.1M | −$139.3M | −$226.2M | −$170.3M | −$69.2M | −$75.6M |
| LMAT Dec | $31.8M | $30.2M | $22.1M | $29.5M | $37.2M | $74.5M |
| ZLAB Dec | −$226.2M | −$567.5M | −$392.2M | −$205.4M | −$220.5M | −$158.9M |
| LGND Dec | $50.1M | $70.0M | $119.9M | $46.1M | $95.2M | $48.9M |
| WGS Dec | −$117.2M | −$199.8M | −$326.3M | −$185.4M | −$34.0M | $14.3M |
| KRYS Dec | −$40.9M | −$116.3M | −$153.5M | −$100.6M | $119.2M | $188.9M |
| RVMD Dec | −$103.0M | −$153.7M | −$235.2M | −$358.3M | −$567.7M | −$913.7M |
| Peer median | −$103.0M | −$139.3M | −$173.7M | −$136.2M | −$34.0M | $14.3M |
FCF margin, FY2020 to FY2025
Free cash flow / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −629.5% | −168.0% | −110.7% | −97.8% | −46.2% | −18.9% |
| VCEL Dec | 12.0% | 13.5% | 6.1% | 7.7% | −2.4% | 9.0% |
| RYTM Dec | - | n/m | −734.9% | −175.9% | −87.5% | −61.5% |
| TWST Sep | −168.8% | −105.3% | −111.1% | −69.5% | −22.1% | −20.1% |
| LMAT Dec | 24.6% | 19.6% | 13.7% | 15.2% | 16.9% | 29.8% |
| ZLAB Dec | −462.0% | −393.3% | −182.4% | −77.0% | −55.3% | −34.5% |
| LGND Dec | 30.6% | 29.0% | 61.1% | 35.1% | 57.0% | 18.2% |
| WGS Dec | −65.4% | −94.2% | −139.0% | −91.5% | −11.1% | 3.3% |
| KRYS Dec | - | - | - | −198.4% | 41.0% | 48.5% |
| RVMD Dec | −239.6% | −523.0% | −664.8% | n/m | - | - |
| Peer median | −65.4% | −94.2% | −125.1% | −73.2% | −6.8% | 6.1% |
Return on equity, FY2020 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | n/m | −22.4% | −44.2% | −37.7% | −22.7% | −26.1% |
| VCEL Dec | 2.1% | −4.4% | −8.7% | −1.4% | 3.5% | 4.7% |
| RYTM Dec | −80.5% | −24.5% | −68.5% | −108.8% | n/m | −141.3% |
| TWST Sep | −41.6% | −26.2% | −27.6% | −32.8% | −44.2% | −16.4% |
| LMAT Dec | 12.3% | 10.6% | 7.7% | 10.1% | 13.1% | 14.7% |
| ZLAB Dec | −23.0% | −51.1% | −42.4% | −42.0% | −30.6% | −24.5% |
| LGND Dec | −0.4% | 7.0% | −5.6% | 7.4% | −0.5% | 12.2% |
| WGS Dec | n/m | −63.2% | n/m | −77.1% | −21.3% | −6.8% |
| KRYS Dec | −11.0% | −11.7% | −26.8% | 1.4% | 9.4% | 16.8% |
| RVMD Dec | −22.8% | −31.0% | −36.3% | −23.9% | −26.5% | −69.3% |
| Peer median | −16.9% | −24.5% | −27.2% | −23.9% | −10.9% | −6.8% |
Debt / equity, FY2020 to FY2025
Total debt / shareholders' equity at the year end.
EPS (diluted), FY2020 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| PRCT Dec | −$14.47 | −$3.63 | −$1.96 | −$2.24 | −$1.75 | −$1.72 |
| VCEL Dec | $0.06 | −$0.16 | −$0.35 | −$0.07 | $0.20 | $0.32 |
| RYTM Dec | −$3.04 | −$1.40 | −$3.47 | −$3.20 | −$4.34 | −$3.11 |
| TWST Sep | −$3.57 | −$3.15 | −$4.04 | −$3.60 | −$3.60 | −$1.30 |
| LMAT Dec | $1.04 | $1.25 | $0.93 | $1.34 | $1.93 | $2.52 |
| ZLAB Dec | −$0.35 | −$0.76 | −$0.46 | −$0.35 | −$0.26 | −$0.16 |
| LGND Dec | −$0.18 | $3.31 | −$1.98 | $2.94 | −$0.22 | $6.13 |
| WGS Dec | −$47036.00 | −$2.27 | −$53.63 | −$7.23 | −$1.94 | −$0.73 |
| KRYS Dec | −$1.71 | −$3.13 | −$5.49 | $0.39 | $3.00 | $6.84 |
| RVMD Dec | −$2.01 | −$2.57 | −$3.08 | −$3.86 | −$3.58 | −$5.95 |
| Peer median | −$1.71 | −$1.40 | −$3.08 | −$0.35 | −$0.26 | −$0.16 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out PRCT and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: PRCT's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.